Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359327 | 0.87 | ASAH1 (0.54) | ASAH1TDP1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL4952864 | 0.75 | ASAH1 (0.39) | ASAH1TDP1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL7413126 | 0.74 | MAPT (0.57) | TDP1SMN1; SMN2LMNAHSD17B10L3MBTL1 | |
| SCHEMBL2022520 | 0.73 | CYP11B1 (0.75) | TDP1CYP11B1CYP11B2SMN1; SMN2HTT | |
| SCHEMBL1800353 | 0.71 | TDP1 (0.48) | TDP1CYP11B1CYP11B2SMN1; SMN2HTT | |
| SCHEMBL4953476 | 0.71 | FGFR1 (0.40) | ASAH1TDP1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL4953499 | 0.71 | FGFR1 (0.40) | ASAH1TDP1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL15022038 | 0.70 | TDP1 (0.52) | TDP1CYP11B1CYP11B2SMN1; SMN2HTT | |
| SCHEMBL1062170 | 0.70 | TDP1 (0.44) | TDP1CYP11B1CYP11B2SMN1; SMN2HTT | |
| SCHEMBL7377916 | 0.69 | SMN1; SMN2 (0.51) | SMN1; SMN2ALOX15HSD17B10NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745443-B2 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070173489-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-26 | — | — | US | disclosed |
| US-7235558-B2 | Inhibitors of the GPIb—vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| EP-1509516-B1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-31 | — | — | EP | disclosed |
| EP-1509516-A1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | Aventis Pharma Deutschland GmbH (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040067980-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| WO-2003104221-A1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
| EP-1369420-A1 | Inhibitors of the GPib - vWF interaction | Aventis Pharma Deutschland GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173489-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | F13B, F11, F12 | ASAH1 2861/4885TDP1 3675/4885CYP11B1 2653/4885 |
| US-20040067980-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | F13B, F11, F12 | ASAH1 2906/4885TDP1 3209/4885CYP11B1 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.